Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Onconova Therapeutics, Inc. | a2234139zex-32_2.htm |
| EX-32.1 - EX-32.1 - Onconova Therapeutics, Inc. | a2234139zex-32_1.htm |
| EX-31.2 - EX-31.2 - Onconova Therapeutics, Inc. | a2234139zex-31_2.htm |
| EX-31.1 - EX-31.1 - Onconova Therapeutics, Inc. | a2234139zex-31_1.htm |
| EX-21.1 - EX-21.1 - Onconova Therapeutics, Inc. | a2234139zex-21_1.htm |
| 10-K - 10-K - Onconova Therapeutics, Inc. | a2234139z10-k.htm |
QuickLinks -- Click here to rapidly navigate through this document
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statements (Form S-8 No. 333-191161, Form S-8 No. 333-194228, Form S-8 No. 333-204210, Form S-8 No. 333-210694, Form S-8 No. 333-215575, Form S-8 No. 333-222400, Form S-3 No. 333-221684, Form S-1 No. 333-207533, Form S-1 No. 333-211769 and Form S-1 No. 333-222374) of our report dated March 16, 2018, with respect to the consolidated financial statements of Onconova Therapeutics, Inc. included in this Annual Report (Form 10-K) for the year ended December 31, 2017.
| /s/ Ernst & Young LLP | ||
| Philadelphia, Pennsylvania March 16, 2018 |
Consent of Independent Registered Public Accounting Firm